Market Place
Sourcing Support
UroGen Pharma Reports Q3 2024 Results & UGN-102 Launch Plans
06 Nov 2024 //
BUSINESSWIRE
UroGen Pharma to Present at Guggenheim Securities Health Conference
05 Nov 2024 //
BUSINESSWIRE
UroGen to Report Q3 2024 Results on Nov 6, 2024
30 Oct 2024 //
BUSINESSWIRE
ENVISION Trial Shows 82.3% Response Duration for UGN-102
28 Oct 2024 //
BUSINESSWIRE
UroGen Announces FDA Acceptance of its NDA for UGN-102
15 Oct 2024 //
BUSINESSWIRE
UroGen Appoints Chris Degnan as Chief Financial Officer
09 Oct 2024 //
BUSINESSWIRE
First Patient Dosed In Phase 3 Trial Of UGN-103 For Bladder Cancer
02 Oct 2024 //
BUSINESSWIRE
UroGen Receives Patent For Next-Gen Mitomycin Products
16 Sep 2024 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2024 //
BUSINESSWIRE
UroGen Submits NDA Seeking Approval For UGN-102 For Invasive Bladder Cancer
14 Aug 2024 //
BUSINESSWIRE
UroGen Pharma Accelerates UGN-102 NDA And Reports Q2 2024 Results
13 Aug 2024 //
BUSINESSWIRE
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday
05 Aug 2024 //
BUSINESSWIRE
UroGen Pharma Announces Pricing Of Public Offering Of Shares And Warrants
17 Jun 2024 //
BUSINESSWIRE
UroGen Pharma Announces Public Offering Of Shares And Pre-Funded Warrants
17 Jun 2024 //
GLOBENEWSWIRE
UroGen touts `unprecedented` data for gel-based bladder cancer therapy
14 Jun 2024 //
PRESS RELEASE
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months
13 Jun 2024 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
06 Jun 2024 //
BUSINESSWIRE
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
03 Jun 2024 //
BUSINESSWIRE
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
22 May 2024 //
BUSINESSWIRE
UroGen Announces ENVISION Data, Jelmyto Durability, Q1 2024 Results
13 May 2024 //
BUSINESSWIRE
UroGen Pharma to Participate at Upcoming Investor Conferences
07 May 2024 //
BUSINESSWIRE
UroGen highlights result of sub-analysis from first & largest real-world patient
06 May 2024 //
PHARMABIZ
Real-World Analysis: 86% 24-Month RFS With JELMYTO® In Responders
05 May 2024 //
BUSINESSWIRE
UroGen`s ATLAS Shows UGN-102 Durability In Low-Risk NMIBC At AUA
04 May 2024 //
BUSINESSWIRE
UroGen To Report Q1 2024 Results On May 13
03 May 2024 //
BUSINESSWIRE
UroGen New AUA Data Highlights Urothelial Cancer Portfolio
17 Apr 2024 //
PRESS RELEASE
UroGen Gets IND For UGN-103 NMIBC Next-Gen Mitomycin
15 Apr 2024 //
BUSINESSWIRE
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
03 Apr 2024 //
BUSINESSWIRE
UroGen Pharma Delivers Double Digit JELMYTO® Growth
14 Mar 2024 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2024 //
BUSINESSWIRE
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results
04 Mar 2024 //
BUSINESSWIRE
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
26 Feb 2024 //
BUSINESSWIRE
UroGen Pharma to Participate at Upcoming Investor Conferences
01 Feb 2024 //
BUSINESSWIRE
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
24 Jan 2024 //
BUSINESSWIRE
UroGen Secures Exclusive License from medac GmbH
17 Jan 2024 //
BUSINESSWIRE
UroGen Pharma to Participate in the B. Riley Healthcare Conference
11 Jan 2024 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Dec 2023 //
BUSINESSWIRE
UroGen Pharma Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
UroGen Pharma to Report Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
03 Oct 2023 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Sep 2023 //
BUSINESSWIRE
UroGen Pharma to Present at Upcoming Investor Conferences
31 Aug 2023 //
BUSINESSWIRE
UroGen Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
10 Aug 2023 //
BUSINESSWIRE
UroGen Pharma to Report Second Quarter 2023 Financial Results
02 Aug 2023 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jul 2023 //
BUSINESSWIRE
UGN-102, in Development for LG-IR-NMIBC, Met Primary Endpoints
27 Jul 2023 //
BUSINESSWIRE
UroGen Announces $120 Million Private Placement of Ordinary Shares
27 Jul 2023 //
BUSINESSWIRE
UroGen nabs $120M to support potential 2024 NDA filing
27 Jul 2023 //
ENDPTS
UroGen Announces the Appointment of James Robinson to its Board of Directors
25 Jul 2023 //
BUSINESSWIRE
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation
10 Jul 2023 //
BUSINESSWIRE
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
06 Jul 2023 //
BUSINESSWIRE
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological
20 Jun 2023 //
BUSINESSWIRE
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 Jun 2023 //
BUSINESSWIRE
UroGen Pharma to Present at Upcoming Investor Conferences
02 Jun 2023 //
BUSINESSWIRE
UroGen Pharma Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
UroGen Pharma to Report 2023 1Q FYR on Thursday, May 11, 2023
04 May 2023 //
BUSINESSWIRE
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports
01 May 2023 //
BUSINESSWIRE
New Retrospective Study Presented at AUA 2023 Similar Outcomes Utilizing JELMYTO
30 Apr 2023 //
BUSINESSWIRE
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
25 Apr 2023 //
BUSINESSWIRE
